Medical researchers who are interested in initiating a thalassemia-related project or who have an existing project that requires additional funding: The Cooley’s Anemia Foundation may be just what you need.
CAF has a decades-long history of supporting innovative and important research in thalassemia. Our established and respected Medical Fellowship program has funded numerous early career individuals who have continued to stay in the thalassemia field and make important contributions to the scientific and clinical study of thalassemia.
Our Support for Ongoing Clinical Research in Thalassemia Grants and Clinical Trials in Thalassemia Cell and Gene Therapy Grants are aggressively pushing forward the understanding of issues of concern to the growing thalassemia population and helping to propel advances in areas of primary importance.
April 6, 2018 – Sangamo Therapeutics and Bioverativ Therapeutics have begun a Phase 1/2 study of gene editing in patients with transfusion-dependent beta-thalassemia in the United States. This trial will investigate whether increasing the production of fetal hemoglobin can reduce or eliminate the need for blood transfusions. Participating patients will have their CD34+ blood stem cells […]
October 19, 2017 –The University of California, San Francisco (UCSF) is currently recruiting participants for the first ever clinical trial performing in utero stem cell transplantations on fetuses affected with alpha-thalassemia major (ATM). CAF speaks with Dr. Tippi MacKenzie, a pediatric and fetal surgeon at UCSF Benioff Children’s Hospital who is leading this clinical trial […]
July 10, 2017– CAF is pleased to announce that five new Cooley’s Anemia Foundation Medical Research Fellowships and three renewal Fellowships have been awarded for the 2017-2018 grant cycle. The total amount of funding for the 8 research Fellowships is $260,000. These Fellowship recipients were assessed on the basis of the quality of the scientific […]
September 27, 2016- CAF is pleased to announce that four new Cooley’s Anemia Foundation Medical Research Fellowships and one renewal Fellowship have been awarded for the 2016-2017 grant cycle. In addition, this year we have awarded a new Clinical Research Grant to support ongoing clinical research in thalassemia. The total amount of funding for the […]
October 28, 2015 – A packed house of 240 clinicians, scientists, nurses, industry, consumers and other participants attended the 10th Cooley’s Anemia Symposium in Rosemont, IL from October 18-22. This invaluable meeting, presented by the Cooley’s Anemia Foundation (CAF) and the New York Academy of Sciences(NYAS) is an anticipated and milestone event held only every […]
July 29, 2015 – Three new Cooley’s Anemia Foundation Medical Research Fellowships have been awarded for the 2015-2016 grant cycle. Combined with the three Fellowships which have been renewed from the previous cycle, the total amount of research funding for the current cycle comes to $195,000. The recipients were selected by members of the CAF […]
February 2, 2015 – Thalassaemia International Federation ( TIF) has announced a new thalassemia fellowship opportunity, established in honor of the late Renzo Galanello, Professor of Pediatrics at the University of Cagliari, Italy, and Director of the 2nd Pediatric Clinic, Department of Biomedical Sciences and Biotechnologies, Ospedale Regionale per le Microcitemie. Dr. Galanello was a respected and […]
December 11, 2014 – Exciting data from studies looking at new treatments for thalassemia presented at the annual meeting of the American Society of Hematology builds upon science supported by the Cooley’s Anemia Foundation and gives hope for the development of significant new treatments for the genetic blood disorder known as thalassemia. Two of the […]
August 25, 2014 – New explorations in gene editing. Connections between thyroid hormones and hemoglobin. Efficiency and safety in gene therapy. Using a protein to control iron. These are the ideas behind the four exciting new studies being funded by the Cooley’s Anemia Foundation this year. These new fellowships join four renewed fellowships and a […]
bluebird bio, a Cambridge, MA- based biotechnology company, is sponsoring the Northstar Study, investigating gene transfer as a curative option for beta-thalassemia. More information about the study, including eligibility requirements, can be found at http:///www.northstarstudy.com. The Northstar Study is now enrolling adults who are transfusion dependent and diagnosed with a beta thalassemia major. The goal […]
